MitoQ

Prescribing exercise – the “miracle cure”

Latest articles

Drive to end cancer could pioneer diagnostic technology

Blood test that can determine a cancer signal origin with high accuracy is now available on prescription in the US and could lead to...

Small is mighty when it comes to mitochondria supplements

Optimise, energise, revitalise – MitoQ is on a mission to supplement your mitochondrial health. Coenzyme Q10 – or CoQ10 – is made naturally in the...

Improving speed and accuracy in Alzheimer’s patients

Phase 2a study of patients with Alzheimer's or Parkinson's finds that ANVS401 treatment leads to significant improvement in speed and accuracy. Annovis Bio Inc, a...

New SIRT6 activator supplement hits the market

Sirtuin 6, the protein making waves in the longevity pool, can now be activated by a brand-new supplement. SIRT6 is a protein with an important...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...
fundraising

Editor's picks

Drive to end cancer could pioneer diagnostic technology

Blood test that can determine a cancer signal origin with high accuracy is now available on prescription in the US and could lead to...

Small is mighty when it comes to mitochondria supplements

Optimise, energise, revitalise – MitoQ is on a mission to supplement your mitochondrial health. Coenzyme Q10 – or CoQ10 – is made naturally in the...

Improving speed and accuracy in Alzheimer’s patients

Phase 2a study of patients with Alzheimer's or Parkinson's finds that ANVS401 treatment leads to significant improvement in speed and accuracy. Annovis Bio Inc, a...
MitoQ

Click the globe for translations.

EXi targets chronic illness with digital personalised platform for prescribing exercise.

British start-up EXi is making waves with its app for prescribing personalised activity programmes. The app provides programmes that address any combination of 23 health conditions, including diabetes, heart disease and depression.

A 12 week, 100 person clinical pilot study recently completed by EXi showed that the app was effective across a wide range of health metrics, including improvements in blood glucose levels, resting heart rate, blood pressure, abdominal circumference, BMI, 6-minute walk test and mood.

Longevity.Technology: Exercise is one of the few longevity therapies that has delivered proven results in humans. Indeed, a few years ago, the UK’s Academy of Medical Royal Colleges dubbed it “the miracle cure”. But knowing exactly what exercise to prescribe for an individual can be difficult and EXi is addressing this challenge head on. We caught up with the company’s co-founder and clinical director Carron Manning to find out more.

Manning, a chartered physiotherapist for more than 20 years, founded EXi along with her husband Lewis, also a physio, after realising that exercise was not being properly considered in the treatment of chronic disease.

Carron Manning EXi hero
Carron Manning, Co-founder and clinical director, EXi

“I’ve been prescribing exercise for a long time, for people with all types of illnesses, injuries, all the way up to elite athletes – the full spectrum,” she says. “And we could see that there was a huge gap in terms of medicine for people with chronic diseases like diabetes, heart disease, hypertension and cancer. These people are managed primarily through drugs and medical based treatments, whereas the reasons that they are in that situation in the first place are often due to their lifestyle, diet, lack of activity, and a few other factors. But all of that is not really being addressed.”

Targeting chronic disease

The Mannings realised there was potentially a huge opportunity to target chronic disease with exercise, but that most doctors and general practitioners simply don’t have the training in physical activity to effectively prescribe it.

“We could see that technology was really starting to catch up with where we needed it to be,” she says. “So we thought we could actually do something about it, we could put everything together to make an intelligent, automated system based on medical guidelines. It had to be entirely robust and evidence-based, because clinicians will throw things out immediately if they aren’t evidence based – as I would.”

After spending around a year researching and developing a system, the company put together the first iteration of its app, which received positive feedback from Harvard University and ukactive in 2016.

“People could see that we were different, because it was the first app to do this,” says Manning.

Grace McNamara
Grace McNamara, CEO, EXi

The company then spent some years refining the product and building out its team, including bringing on board Grace McNamara as CEO, who joined from Apple where she led the company’s health and fitness strategic initiatives in Europe and the Middle East.

Prescribing exercise like drugs

Fast forward to today, and the company has a robust, clinically validated app that tracks a wide range of metrics to deliver fully automated, highly personalised exercise programmes. With both iOS and Android apps, EXi can draw data from almost any wearable that puts data into Apple HealthKit or Google Fit.

“We are prescribing exercise in the same way as a doctor prescribes drugs, specifically for therapeutic purposes, to both help prevent and manage medical conditions,” says Manning. “We know, for example, that exercise will have a profound effect on blood pressure, on circulation, it helps to prevent certain types of cancer. This is the impact of exercise – no drug has ever been created, which has the same molecular or physiological effect as exercise.”

EXi’s programmes are based on the principle of exercise intensity. Working at the correct intensity level is key to enabling people with chronic conditions to exercise safely and to ensure they are getting the maximal health benefits.

“We know there’s a specific dose response with exercise, so we know exactly what the effects will be for any given population based on research,” says Manning. “We know how hard to push somebody safely, we know how effective it’s going to be on their medical condition. And we’ve done this for any combination of 23 medical conditions.”

Patients can download the app themselves to get started, but clinicians also have access via a dashboard where they can view all their patients in a single view. Health outcome measures are tracked on a weekly basis, including a GPS-enabled six minute walking test, resting heart rate, blood pressure, waist circumference, and BMI.

Proving the impact

EXi is currently engaged in research projects with University College London, King’s College and others to prove its effectiveness and impact on patients’ lives, but also the potential economic impact. The app is free for patients and is currently available to healthcare providers at a nominal cost, while EXi works to prove that it can “fundamentally shift the needle on care delivery”.

While currently targeting some of the key national NHS frameworks in the UK, EXi also expects to enter the US market later this year or next, with the national Medicare and Medicaid programmes likely to be a key focus.

“One of our fundamentals is that everyone should have access to healthcare, and I think that ‘get healthy, get active’ is a statement that everyone should hear and be able to get a prescription for that regardless of their status,” says Manning.

To date, EXi has raised around £1.5 million in angel funding, and expects it will need to raise another £1.5 – £2 million by the end of the year or early next year.

Images courtesy of EXi

Comment on this article

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.
MitoQ

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
fundraising

Related articles

Occuity – shining a light on health and longevity

Forget windows to the soul, Occuity's non-invasive smart diagnostic tech provides a window to health and wellness. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited)...

Workforce wellbeing platform scales up

Digital twin platform syd gets deployed by NHS, closes first workplace wellbeing deal in US and kicks off independent studies. DISCLOSURE: Longevity.Technology (a brand...

PCL Health embarks on preventive care trial with NHS

PCL Health enables preventive care by driving actionable insights from a wide range of health data. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Wyss Center gets CE mark for NeuroKey brain-AI interface

The Wyss Center announces CE mark for its brain-computer interface software for communication, NeuroKey BCI, which enables communication in real time. The Wyss Center, which...

Building a virtual model to solve human aging

Peter Fedichev explains how Gero is using AI and activity data to accelerate our understanding of human aging. We recently reported on AI firm Gero’s...
Supps report ad middle